Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM60 and Pembrolizumab in Advanced Melanoma and Metastatic NSCLC
NCT05709821Phase 2Terminated
- Sponsor
- iOx Therapeutics
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of IMM60 in non-small cell lung cancer (NSCLC) and melanoma (6 arms), sponsored by iOx Therapeutics. Primary endpoints: Maximum Tolerated Dose, Safety and Adverse Events and 1 more. Started Nov 2023; status: terminated.
02
Drugs
IMM60
03
Conditions
non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT05709821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709821.